Article
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Cytotherapy - 1 Mar 2024
Shafer Paul, Leung Wingchi K, Woods Mae, Choi Jong Min, Rodriguez-Plata Carlos M, Maknojia Arushana, Mosquera Andres, Somes Lauren K, Joubert Jarrett, Manliguez Anthony, Ranjan Rashi, Burt Bryan, Lee Hyun-Sung, Zhang Bing, Fuqua Suzanne, Rooney Cliona, Leen Ann M, Hoyos Valentina
Abstract excerpt
T cell receptor engineered T cell (TCR T) therapies have shown recent efficacy against certain types of solid metastatic cancers. However, to extend TCR T therapies to treat more patients across additional cancer types, new TCRs recognizing cancer-specific antigen targets are needed. Driver mutations in AKT1, ESR1, PIK3CA, and TP53 are common in patients with metastatic breast cancer (MBC) and if immunogenic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.